Uttar Pradesh Journal of Zoology

Volume 45, Issue 21, Page 106-129, 2024; Article no.UPJOZ.4315
ISSN: 0256-971X (P)

Comprehensive Analysis of Monkey Pox Outbreak Dynamics and Prevention Strategies

Ajit Pal Singh [a++*]

[a] *Department of Medical Lab Technology, SSAHS, Sharda University, Gr. Noida, Uttar Pradesh, India.*

Author's contribution

The sole author designed, analyzed, interpreted and prepared the manuscript.

Article Information

DOI: https://doi.org/10.56557/upjoz/2024/v45i214621

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://prh.mbimph.com/review-history/4315

Review Article

Received: 09/09/2024
Accepted: 12/11/2024
Published: 18/11/2024

ABSTRACT

Monkey pox, a zoonotic viral illness, has lately undergone a global revival, prompting considerable public health concerns. This abstract seeks to deliver a thorough summary of the outbreak, encompassing its transmission, symptoms, prevention efforts, and the significance of international collaboration. Most cases of monkey pox spread through intimate contact with an infected person or animal. This may happen via direct contact with lesions, respiratory droplets, or contaminated objects. Common symptoms encompass fever, headache, tiredness, myalgia, lymphadenopathy, and a rash. Although the majority of instances are minor, serious sickness may manifest in specific populations, including children, pregnant women, and immunocompromised individuals. Several techniques are needed to avert the dissemination of monkey pox. These measures encompass refraining from close contact with diseased persons or animals, maintaining proper hygiene, and receiving vaccinations. Vaccination is especially crucial for high-risk groups, including healthcare professionals and those with compromised immune systems. Global cooperation is essential for properly managing the monkey pox outbreak. The World Health Organisation (WHO) and other international health entities have been instrumental in orchestrating global responses, delivering

[++] *Assistant Professor;*
**Corresponding author: Email: ajit.singh1@sharda.ac.in;*

Cite as: *Singh, Ajit Pal. 2024. "Comprehensive Analysis of Monkey Pox Outbreak Dynamics and Prevention Strategies". UTTAR PRADESH JOURNAL OF ZOOLOGY 45 (21):106-29. https://doi.org/10.56557/upjoz/2024/v45i214621.*

technical support, and facilitating information exchange. Collaborative initiatives have concentrated on monitoring, case management, and the creation and dissemination of vaccines and treatments. As the monkey pox outbreak progresses, it is crucial to maintain vigilance and execute effective preventive strategies. Comprehending the transmission pathways, symptoms, and preventive measures enables people and communities to significantly reduce the effect of this disease.

Keywords: Global collaboration; prevention; symptoms; transmission; zoonotic.

1. INTRODUCTION

1.1 Definition of Monkey Pox

Monkey Pox, a rare disease, is caused by the monkey pox virus, which belongs to the same family as the smallpox virus. It is characterized by a skin eruption that occurs first on the face, hands, or feet and then spreads to other regions of the body. The rash advances through several stages, including macules, vesicles, and crusts. Supplementary symptoms may include fever, headache, muscle pain, back pain, fatigue, swollen lymph nodes, and sore throat. Monkey Pox transmission can occur through direct contact with an infected person or animal or contaminated materials. The majority of Monkey pox cases are mild, with people often achieving full recovery within several weeks. However, specific individuals, particularly those with weakened immune systems, may have severe illness. Vaccination provides immunity against Monkey Pox. Throughout human history, infectious diseases have consistently threatened global health. From the Black Death in the 14th century to the Spanish Flu in 1918, pandemics have significantly influenced communities, economics, and cultures. These outbreaks frequently transpired during phases of swift urbanisation, globalisation, and demographic expansion, establishing optimal circumstances for disease dissemination.

1.2 Recent Outbreaks

Recent research on monkey pox outbreaks highlighted the thousands of cases reported globally by the World Health Organisation in 2022. This research reveals a large increase in cases that occurred outside of countries where the disease is endemic. Changes in social behaviour, increased international travel, and potential gaps in smallpox immunization, which historically offered cross-protection, link to this increase. The findings of a study that was published in Nature found that these factors are all connected to this situation. Genetic research has demonstrated that the virus is evolving, with certain forms exhibiting greater transmissibility. Public health responses are undergoing additional improvements, including the implementation of targeted vaccination regimens and increased surveillance (Guagliardo, 2024). If we fail to implement appropriate interventions, experts warn that monkey pox could spread to non-endemic locations, posing ongoing challenges to public health. Therefore, it is more important than ever to continue monitoring and studying.

In recent decades, several notable outbreaks have highlighted the ongoing challenges posed by infectious diseases:

a) **SARS (Severe Acute Respiratory Syndrome):** Emerging in 2002, SARS caused a global health scare. While it was eventually contained, it demonstrated the potential for rapid spread and severe consequences (Pal et al., 2024).
b) **H1N1 Influenza Pandemic:** In 2009, a new strain of influenza, H1N1, caused a global pandemic. Although the mortality rate was relatively low, the pandemic strained healthcare systems and disrupted economies worldwide (Ismael et al., 2024).
c) **Ebola Virus:** Outbreaks of Ebola virus have occurred in West Africa and the Democratic Republic of Congo in recent years. These outbreaks were characterized by high mortality rates and challenges in containment due to the virus's highly contagious nature (Ghana, 2024).
d) **COVID-19 (Coronavirus Disease 2019):** The COVID-19 pandemic, which began in late 2019, is one of the most significant global health crises in recent history. It caused widespread illness, death, and economic disruption on a global scale (Cevik et al., 2024).

1.3 Factors Contributing to Outbreaks

The revival of monkey pox epidemics in recent years can be due to a complex interaction of

biological, environmental, and socio-political elements. This interaction has created a complicated situation. First and foremost, the zoonotic origin of the monkey pox virus, which typically dwells in animal hosts such as rodents and non-human primates, highlights the significance of interactions with wildlife in the dynamics of transmission. Increased human encroachment into wildlife habitats due to deforestation, urbanisation, and agricultural development has increased the danger of spill over incidents. This has facilitated the transmission of the virus to humans. A further point to consider is that the increase in international travel and trade has made it possible for humans and animals to move around more quickly, which has increased the likelihood that epidemics may spread over national boundaries. In addition to ecological considerations, social determinants of health play a significant part in determining the degree to which populations are susceptible to monkey pox. Regions with inadequate disease monitoring systems, disease surveillance systems, and weak public health infrastructure are particularly vulnerable. It is possible for outbreaks to become more severe if timely diagnosis and treatment are not provided, which can result in increased transmission rates. The socio-cultural context of outbreaks also affects public perception and response. The stigmatization of sick people, which is frequently associated with the sexual transmission channels found in recent outbreaks, might impede the effectiveness of public health messages and deter individuals from seeking medical attention or reporting symptoms (de Araújo et al., 2024). The virus has also spread due to behavioural reasons, such as changes in sexual habits and higher rates of personal contact within communities. These factors have led to the transmission of the virus. The current epidemics have brought to light the importance of close interpersonal contact in the spread of the disease, particularly within networks where sexual behaviours are common. Consequently, in order to effectively implement preventative interventions, public health solutions need to take behavioural dynamics into consideration. The aftermath of the COVID-19 pandemic has impacted the global health landscape, resulting in a strain on healthcare resources and a restructuring of public health priorities. It is possible that the disruption of routine vaccination programs and efforts to monitor diseases has resulted in a reduction in the population's immunity to a variety of viruses, including monkey pox. Disinformation and distrust in health authorities fuel ongoing vaccine hesitancy, complicating efforts to create herd immunity against outbreaks. The genetic variety of the monkey pox virus itself adds to the complexity of the situation. Due to the possibility of variants displaying distinct transmission and pathogenicity features, it is crucial to conduct ongoing research and monitoring to fully understand the consequences these variants may have on public health. Historically, research on neglected tropical illnesses has received little financing, which frequently hinders the development of effective vaccines and therapies. The underfunding of this research further underscores its intricacy. The most recent epidemics of monkey pox are the consequence of a convergence of elements relating to the environment, society, and healthcare. It is necessary to take a comprehensive and multi-disciplinary approach in order to address these outbreaks. This approach should incorporate ecological conservation, community participation, and enhanced health systems in order to reduce the likelihood of repeat outbreaks and assure the safety of public health. Many different factors influence both the development and propagation of infectious diseases. Globalization, which has led to increased travel and trade, has made it easier for infectious diseases to spread quickly across international borders. Urbanization, which is characterized by places with a high population density, creates conditions that are ideal for the transmission of diseases. Alterations in environmental conditions brought about by climate change have the potential to influence the distribution and prevalence of specific infections. The destruction of ecosystems caused by deforestation and the loss of habitat creates situations in which people come into contact with wild animals that may carry dangerous diseases. Additionally, the abuse and improper use of antibiotics can result in the growth of bacteria that are resistant to them, which significantly increases the difficulty of treating illnesses. These interrelated elements highlight the complexity of infectious disease outbreaks and underscore the need for comprehensive policies for global health. To effectively respond to outbreaks, we need a coordinated global effort that encompasses surveillance and early detection, rapid containment, treatment and care, vaccine research, and international cooperation. It is possible to improve our preparedness and response to impending health crises by gaining an understanding of the historical background and the elements that influence epidemics. Possible pandemics threaten global health, the

economy, and society (Schuele et al., 2024). A number of adverse health effects have been observed, including increased mortality rates, overwhelmed healthcare systems, and long-term health impacts. The disruption of supply networks, the failure of businesses, the increase in unemployment, and the volatility of the financial system are all economic effects. Fear, ambiguity, a sense of alienation, and feelings of isolation, stigma, and bias are all examples of social implications. Interdependence on the economic front, difficulties in international cooperation, and geopolitical concerns are all examples of the global ramifications. A potential pandemic presents a significant risk, necessitating immediate action to mitigate its impact. By first understanding the potential implications and then planning accordingly, we can improve the safety of our communities and ourselves.

2. UNDERSTANDING THE VIRUS

Viruses, being microscopic entities, rely on various mechanisms to spread from one host to another. These transmission routes can be broadly categorized into contact and airborne. Contact transmission involves the physical touching of an infected person or contaminated surface, while airborne transmission occurs through respiratory droplets or aerosols released into the air. Examples of viruses that can be transmitted through both contact and airborne routes include COVID-19 and influenza. To prevent the spread of viruses, it is essential to practice hand hygiene, respiratory etiquette, and maintain physical distance. Vaccination is also crucial in preventing many viral infections. While some viral infections can be treated with antiviral medications, supportive care is often the primary focus. Emerging viral threats, such as SARS-CoV-2 and MERS-CoV, highlight the importance of ongoing surveillance and preparedness to mitigate their impact (McCollum and Damon, 2014). Understanding these transmission routes, prevention measures, and treatment options is crucial for protecting public health and minimizing the burden of viral diseases.

3. GLOBAL PREPAREDNESS AND RESPONSE

It is absolutely necessary to have early detection and surveillance methods that are efficient in order to identify and control Monkey Pox outbreaks in a timely manner. The implementation of these systems requires a coordinated approach that incorporates heightened surveillance, quick laboratory testing, contact tracing, data administration and analysis, risk assessment and mitigation, international collaboration, and community participation. Countries like the United States and the United Kingdom have successfully adopted early detection and surveillance systems. These countries have utilized a combination of active case discovery, sentinel surveillance, and syndromic surveillance in order to identify and track cases of Monkey Pox (Thornhill et al., 2022). Despite the proven benefits of these systems, obstacles such as limited resources, data quality issues, and public opposition may hinder their implementation. Given the constant evolution of the Monkey Pox virus, it is crucial to continuously monitor new varieties and adapt surveillance techniques accordingly. In addition, the incorporation of technology, which may include digital tools and data analytics, has the potential to improve early detection and monitoring activities. Public health authorities are able to efficiently monitor the spread of measles. They are also able to identify outbreaks early on and take timely action to prevent future transmission of the disease (Scarpa et al., 2024). Solving these problems and exploiting technological improvements makes this possible. Given the recent advancements in global preparedness and response to monkey pox, it's crucial to emphasize the ongoing challenges the illness poses, especially considering the outbreaks in non-endemic areas since 2022. Included among the most important strategies are the administration of the JYNNEOS vaccination to high-risk groups and the treatment with the antiviral medication Tecovirimat. Studies on risk factors and genetic surveillance have influenced public health initiatives, while research has clarified transmission dynamics, demonstrating that the virus spreads by direct contact, respiratory droplets, and contaminated items. In addition, research has revealed that the virus spreads through environmental variables. When it comes to combating stigma and disinformation, community engagement is absolutely necessary, and the World Health Organization has set guidelines for improved surveillance and response initiatives. Long-term surveillance, vaccine research, and the incorporation of monkey pox preparedness into broader global health frameworks are the primary areas of attention for future approaches. These steps are intended to strengthen resilience against comparable zoonotic threats.

Table 1. It provides a comprehensive overview of the monkey pox virus, covering its characteristics, transmission, symptoms, and public health measures. Let me know if you need more details or a specific focus!

Aspect	Details
Virus Type Family Genus	Double-stranded DNA virus Poxviridae Orthopoxvirus
Transmission	- Direct contact with infected animals (e.g., rodents) - Human-to-human contact (respiratory droplets, skin lesions) - Contaminated materials (bedding, clothing)
Symptoms	- Fever - Rash (similar to chickenpox) - Muscle aches - Headaches - Swollen lymph nodes
Incubation Period	Typically 6 to 13 days (can range from 5 to 21 days)
Diagnosis	- Clinical evaluation - PCR testing of lesions or bodily fluids - Serological tests
Treatment	- Supportive care (hydration, pain management) - Antivirals (e.g., tecovirimat for severe cases)
Prevention	- Vaccination (ACAM2000, JYNNEOS) - Avoiding contact with infected individuals - Good hygiene practices
Geographic Distribution	Historically endemic in Central and West Africa; recent outbreaks in other regions
Public Health Response	- Surveillance and contact tracing
	- Community education and awareness - Vaccination campaigns in outbreak areas
Complications	- Secondary bacterial infections - Encephalitis - Death (rare, but possible, especially in immunocompromised individuals)
Animal Reservoirs	- Primates, rodents (e.g., squirrels, dormice)

3.1 International Cooperation and Coordination in Global Health Crises

International cooperation and coordination are essential for addressing global health crises, such as pandemics and emerging infectious diseases. By working together, countries can share information, resources, and expertise to mitigate the impact of these crises and protect public health worldwide.

Key Areas of International Cooperation and Coordination:

1. **Information Sharing:**

a) **Surveillance Data:** Sharing epidemiological data, including case counts, geographic distribution, and trends (Svecova, 2024).

b) **Genomic Sequencing:** Collaborating on genomic sequencing of pathogens to track their evolution and identify variants of concern (Venkateswaran et al., 2024).

c) **Best Practices:** Exchanging information on effective prevention, treatment, and response strategies (Godinho et al.,2024).

2. **Resource Sharing:**

a) **Medical Supplies:** Providing essential medical supplies, such as personal protective equipment (PPE), diagnostic tests, and vaccines (Zheng et al., 2022).

b) **Healthcare Personnel:** Deploying healthcare workers to areas with high demand or limited capacity (Gehre et al., 2024).

c) **Financial Assistance:** Providing financial support to countries affected by health crises (Indiastari et al.,2024).

3. **Joint Research:**

a) **Vaccine Development:** Collaborating on research and development of vaccines against emerging pathogens (Ravichandran, 2024).
b) **Therapeutic Development:** Developing new treatments and therapies for infectious diseases (Ulaeto et al., 2023).
c) **Diagnostics:** Improving diagnostic tools for rapid and accurate detection of pathogens (Murhula et al., 2023).

4. **Global Health Governance:**

a) **International Health Regulations (IHR):** Strengthening the implementation and enforcement of the IHR to ensure timely reporting and response to public health emergencies (Hemati and Mohammadi-Moghadam, 2024).
b) **WHO Leadership:** Strengthening the leadership role of the World Health Organization (WHO) in coordinating global health responses (Khan and Perveen, 2024).
c) **Regional Cooperation:** Enhancing cooperation among regional health organizations to address specific regional challenges (Patauner et al., 2024).

Recent Implications of International Cooperation and Coordination:

a) **COVID-19 Pandemic:** The COVID-19 pandemic highlighted the importance of international cooperation in addressing global health crises. Countries worked together to share information, develop vaccines, and distribute medical supplies (Fantin and Coelho, 2024).
b) **Emerging Infectious Diseases:** International cooperation is essential for responding to emerging infectious diseases, such as Ebola, Zika, and Mpo 2024.
c) **Antimicrobial Resistance:** Global efforts are needed to address the growing threat of antimicrobial resistance, which can hinder the treatment of infectious diseases (Haqueet al., 2024).
d) **Climate Change:** Climate change is increasing the risk of emerging infectious diseases and exacerbating existing health challenges. International cooperation is necessary to address the health impacts of climate change (Saloni et al., 2024).

Challenges and Opportunities:

a) **Political Divisions:** Political divisions and geopolitical tensions can hinder international cooperation (Araf et al., 2024).
b) **Resource Constraints:** Limited resources and capacity can constrain the ability of countries to respond to health crises (Cai et al., 2024).
c) **Vaccine Equity:** Ensuring equitable access to vaccines and other health interventions is a major challenge (Mattiuzzi et al., 2024).

Despite these challenges, international cooperation and coordination offer significant opportunities to improve global health security and protect populations from emerging and re-emerging infectious diseases. By working together, countries can build a more resilient and equitable global health system.

3.2 The Role of International Health Organizations like WHO, CDC etc., in the Mpox Epidemic

International health organizations, such as the World Health Organization (WHO) and the Centres for Disease Control and Prevention (CDC), have played a crucial role in the Monkey Pox epidemic. These organizations have played a critical role in formulating global responses, coordinating efforts, and implementing initiatives to minimize the impact of the outbreak. These organizations mobilized resources, skills, and networks in order to handle the evolving situation at a time when monkey pox, which was formerly known as monkey pox, developed as a public health concern beyond its historical endemic regions in central and west Africa. The World Health Organisation (WHO), the leading and coordinating authority on global health within the United Nations system, played both extremely important roles in early detection and reaction. Almost immediately, it activated its Emergency Committee in order to conduct an assessment of the situation and to facilitate conversations among member nations regarding the implications of the spread of monkey pox in areas that are not endemic. The recommendations made by this committee were significant in the establishment of rules for surveillance, contact tracing, and risk assessment, all of which are essential for comprehending the dynamics of transmission in innovative settings. Furthermore, the World

Health Organization's (WHO) coordination of research activities focused on understanding the epidemiology, clinical characteristics, and potential efficacy of the virus became essential in establishing a scientific basis for initiatives in public health. Additionally, the organization emphasized the significance of open and honest communication, asking nations to swiftly report incidents in order to improve global awareness and response capabilities. Alongside the efforts of the World Health Organization (WHO), the Centres for Disease Control and Prevention (CDC) used their experience in infectious disease control and prevention to influence national responses, particularly in the United States. The Centres for Disease Control and Prevention (CDC) promptly established and disseminated clinical guidance, laboratory methods for testing, and resources for healthcare practitioners to ensure the correct identification and management of mpox patients (Mitjà et al., 2023). The Centres for Disease Control and Prevention (CDC) included public health alerts, webinars, and instructional materials in their comprehensive communication efforts. The aim of these materials was to educate healthcare professionals and the general public about the risks of transmission and possible preventative measures. The Centres for Disease Control and Prevention (CDC) were able to facilitate real-time monitoring of cases by building a national surveillance system for monkey pox. This allowed for rapid intervention methods and resource allocation where it was required. In addition, the Centres for Disease Control and Prevention (CDC) worked with local health departments and community organizations to emphasize the significance of effective outreach and education that are culturally relevant in order to effectively reach varied communities that are at risk. The goal of this community-based approach was to provide communities with the knowledge and tools necessary to limit transmission, particularly in metropolitan settings where social networks have the potential to magnify the spread of the virus. Furthermore, the global nature of the monkey pox outbreak underscored the need for a coordinated response from the global community. Through strong collaboration with regional health authorities, such as the European Centre for Disease Prevention and Control (ECDC) and the Africa Centres for Disease Control and Prevention (Africa CDC), organizations such as the World Health Organization (WHO) and the Centres for Disease Control and Prevention (CDC) were able to share data, strategies, and resources. This partnership not only made it easier to conduct monitoring across international borders, but it also encouraged the exchange of information regarding the most effective methods for managing outbreaks. As an illustration of the significance of regional cooperation in the fight against infectious diseases, the European Centre for Disease Prevention and Control (ECDC) conducted risk assessments and provided advice on vaccination tactics in the European context. These initiatives informed public health choices across all member states. Concurrently, the experience that the Africa Centres for Disease Control and Prevention (CDC) had in managing endemic cases of monkey pox provided vital insights into efficient containment methods. This experience also reinforced the necessity of integrating expertise from multiple regions in order to improve global health security (Wawina-Bokalanga et al., 2024), The World Health Organisation (WHO) launched a global vaccination campaign in response to the increasing number of measles cases. The WHO recognized that immunization could play a significant role in preventing the disease from spreading further. The organisation campaigned for existing vaccinations like JYNNEOS and ACAM2000, designed for smallpox but also effective against monkey pox. These vaccines were effective against both varieties of the disease. Regarding vaccine tactics, the WHO provided guidelines for prioritizing high-risk populations. These populations include healthcare workers, men who have sex with other men (also known as MSM), and those who have the potential to be exposed to infected individuals. This strategy underscores the importance of targeted vaccination to optimize benefits and ensure equitable access to vaccinations across various regions, particularly those with limited healthcare infrastructure. In addition, the World Health Organization's (WHO) collaboration with vaccine producers and global partners has made it possible to increase the production and distribution of vaccines. This alleviated concerns about potential disruptions in the supply chain that could hinder immunisation efforts. The World Health Organization (WHO) and the Centres for Disease Control and Prevention (CDC) have emphasized the role of public health messaging in the fight against misinformation and stigma linked to monkey pox. Both organisations initiated communication campaigns to inform the general public about the virus, its transmission, and the steps individuals can take to protect themselves and others from the virus. These initiatives aimed to dispel myths

and reduce stigma, especially in areas where the epidemic had a disproportionate impact. The World Health Organisation (WHO) and the Centres for Disease Control and Prevention (CDC) aimed to foster an environment where people could seek medical care and participate in preventative measures without fear of discrimination. As health organizations adapted their communication strategies to suit the specific needs and settings of various communities, it became clear that culturally sensitive messaging was of the utmost importance. The aim was to make the information accessible and relevant to a diverse audience. International health organisations incorporated research and data collection as essential components of their efforts during the monkey pox outbreak. The World Health Organization and the Centres for Disease Control and Prevention (CDC) provided funding for a number of studies that tried to gain knowledge of the transmission dynamics, clinical symptoms, and long-term health implications of the virus. These organisations aimed to establish a robust evidence base to guide public health policies and actions. They did this by providing financing for research initiatives and working in collaboration with academic institutions. The exchange of information across nations and institutions has also contributed to a better understanding of the epidemiology of monkey pox. This has made it possible to more accurately predict the occurrence of potential outbreaks and to allocate resources in a more efficient manner. Furthermore, the World Health Organization's (WHO) emphasis on One Health initiatives, which integrate human, animal, and environmental health, highlighted the interconnectedness of health systems throughout the process of combating zoonotic illnesses such as monkey pox. These organizations seek to improve surveillance and the early detection of potential spill over events from animals to humans by increasing collaboration between the veterinary and human health sectors. This is an essential step in the prevention of future epidemics. The actions taken by the international community in response to the monkey pox outbreak brought to light the difficulties and disparities that exist in the governance of global health (de Oliveira Maldonadoet al., 2024), Different regions continued to have unequal access to healthcare resources, such as vaccines and treatment options, despite the efforts of organizations such as the World Health Organization and the Centres for Disease Control and Prevention (CDC). Countries with low and intermediate incomes frequently encountered substantial obstacles while attempting to acquire the essential medical supplies and support, which resulted in requests for stronger international solidarity and collaboration during these times. The pandemic underscored the necessity of re-evaluating global health systems to ensure economically vulnerable communities receive adequate protection and assistance during a health emergency. Within the context of the global health agenda, initiatives that aim to develop healthcare infrastructure, enhance local skills, and promote self-sufficiency in epidemic preparedness have emerged as key components. Through coordinated responses, research, vaccination methods, and public health messaging, international health organizations, such as the World Health Organization (WHO) and the Centres for Disease Control and Prevention (CDC), have played an important role in managing the monkey pox epidemic. Through their efforts in surveillance, data sharing, and community participation, they have improved both their understanding of the outbreak and their ability to manage it. On the other hand, the challenges encountered underscore the need for ongoing collaboration, equitable healthcare access, and the integration of diverse viewpoints in global health initiatives. As the globe continues to traverse the intricacies of infectious disease outbreaks, the lessons learnt from the mpox epidemic will be essential in shaping future responses to rising health concerns. Specifically, the lessons should be applied to the monkey pox pandemic. For the development of resilient health systems capable of addressing the myriad issues that infectious illnesses present in a connected world, a coordinated global response based on solidarity and teamwork is crucial. International health organisations like the World Health Organisation (WHO) and the Centres for Disease Control and Prevention (CDC) play crucial roles in coordinating worldwide responses to epidemics like the Monkey pox outbreak. These organisations provide crucial leadership, direction, and support to countries impacted by epidemics through their efforts. As an illustration, the World Health Organization (WHO) played a crucial role in the coordination of global surveillance, the provision of technical assistance to countries, and the mobilization of resources during the outbreak of the plague. Sharing epidemiological data, generating public health messages, and providing funding for research and development initiatives were also key contributions made by the Centres for Disease Control and Prevention (CDC). It is absolutely

necessary for internationally recognized health organizations, as well as local and national health authorities, to work together efficiently in order to create and put into action effective response strategies. International health organizations have a responsibility to maintain vigilance and make certain that countries are ready to respond in the event that new strains of measles or other infectious diseases emerge. It is absolutely necessary to make investments in surveillance systems, research and development, and emergency preparedness in order to guarantee the long-term viability of global health security. When it comes to minimizing the effects of epidemics and protecting public health around the world, international health organizations have the potential to play a significant role by providing leadership, coordination, technical help, and resources (LHAMO et al., 2022).

3.3 Global Supply Chains for Monkey Pox Vaccines, Diagnostics, and Therapeutics

The global supply chain for Mpox vaccines, diagnostics, and therapeutics is a complex network involving manufacturers, distributors, governments, and international organizations. Ensuring a robust and equitable supply chain is crucial for effective response to Mpox outbreaks. Key components of the supply chain include vaccine manufacturing, diagnostic manufacturing, therapeutic development and manufacturing, distribution and logistics, and international cooperation. While significant progress has been made in recent years, challenges such as production capacity, accessibility, intellectual property rights, and cold chain infrastructure persist. Specific examples of successful initiatives include the establishment of global vaccine manufacturing hubs and the development of innovative cold chain solutions (Akkilic et al., 2024) As emerging threats, such as new variants of Mpox or other infectious diseases, continue to emerge, a flexible and adaptable supply chain is essential. Technology, including digital tools and data analytics, can play a crucial role in enhancing supply chain efficiency and transparency. Additionally, ensuring sustainability in the global supply chain, including environmental considerations and ethical sourcing practices, is vital. By addressing these challenges and leveraging technology and sustainability, we can strengthen the global supply chain for Mpox vaccines, diagnostics, and therapeutics and ensure a more resilient and equitable system for responding to future outbreaks (Guo et al., 2024).

4. PUBLIC HEALTH MEASURES

4.1 Public Health Measures for Mpox

Public health measures play a crucial role in preventing the spread of Mpox and mitigating its impact. These measures aim to break the chain of transmission, protect vulnerable populations, and reduce the overall burden of the disease.

1. Contact Tracing and Isolation:

a) **Identification of Contacts:** Identifying individuals who have come into close contact with confirmed Mpox cases (Liu et al., 2024).
b) **Contact Notification:** Notifying contacts about their potential exposure and providing guidance on self-monitoring (Can et al., 2024).
c) **Isolation:** Implementing isolation measures for individuals with confirmed or suspected Mpox cases to prevent further transmission (Li et al., 2024).

2. Quarantine Measures:

a) **Quarantine for Contacts:** Quarantining contacts of confirmed Mpox cases for a specified period to monitor for symptoms and prevent disease spread (Adegboye et al., 2024).
b) **Travel Restrictions:** Imposing travel restrictions on areas with high rates of Mpox transmission to limit the spread of the virus.

3. Education and Awareness Campaigns:

a) **Public Health Messaging:** Developing and disseminating clear and concise public health messages about Mpox, including symptoms, transmission, prevention, and treatment.
b) **Community Engagement:** Engaging with communities to raise awareness, address concerns, and promote adherence to public health measures.
c) **Risk Communication:** Providing accurate and timely information to the public to reduce fear and misinformation.

Table 2. It provides a concise overview of the complexities and dynamics involved in the global supply chains for Mpox-related medical products

Aspect	Details
Key Products	Vaccines (e.g., JYNNEOS), Diagnostics (PCR tests, rapid tests), Therapeutics (antivirals, supportive care)
Major Manufacturers	- Vaccines: Bavarian Nordic (JYNNEOS), Sanofi - Diagnostics: Cepheid, Abbott, Roche - Therapeutics: SIGA Technologies (tecovirimat), Chimerix (brincidofovir)
Supply Chain Components	- Raw Material Sourcing - Manufacturing - Quality Control - Distribution & Logistics - Storage (cold chain requirements for some products)
Geographical Considerations	- Vaccine production primarily in North America and Europe - Diagnostics produced globally but concentrated in advanced economies - Therapeutics from specialized manufacturers in the U.S.
Distribution Challenges	- Cold chain logistics for vaccines - Regulatory approvals and compliance across different countries - Political and economic instability in certain regions affecting access
Regulatory Bodies	- WHO (World Health Organization) - CDC (Centers for Disease Control and Prevention) - EMA (European Medicines Agency) - National health authorities
Market Access Strategies	- Partnerships with local governments and NGOs - Price negotiations and tiered pricing for low-income countries - Initiatives for equitable distribution
Current Issues	- Supply shortages during outbreaks - Variability in vaccine uptake due to public perception - Intellectual property rights and access to technology
Future Trends	- Increased investment in mRNA technology for rapid vaccine development - Development of multiplex diagnostics to test for multiple viruses - Strengthening of global health security frameworks

4. Social Distancing and Gathering Restrictions:

a) **Physical Distancing:** Encouraging individuals to maintain physical distance from others, especially in crowded settings.
b) **Gathering Limits:** Limiting the size of gatherings to reduce the risk of transmission.
c) **Remote Work and Learning:** Promoting remote work and online learning to minimize contact.

5. Personal Protective Equipment (PPE) Guidelines:

a) **Healthcare Workers:** Providing appropriate PPE to healthcare workers, including gloves, gowns, masks, and eye protection, to protect themselves and patients.
b) **General Public:** Recommending the use of masks in public settings, especially when physical distancing is difficult to maintain.
c) **Hand Hygiene:** Promoting frequent handwashing with soap and water or using alcohol-based hand sanitizers.

5. Recent Advancements:

a) **Vaccine Development:** The development and deployment of Mpox vaccines have significantly improved our ability to control outbreaks (Natami et al., 2024).
b) **Improved Diagnostic Tools:** Advancements in diagnostic testing have enabled more rapid and accurate identification of Mpox cases.
c) **Targeted Interventions:** Public health measures are increasingly tailored to specific populations and risk factors to maximize their effectiveness.
d) **International Cooperation:** Strengthened international cooperation has facilitated the

sharing of information, resources, and expertise in addressing Mpox outbreaks.

By implementing these public health measures and staying informed about the latest advancements, we can effectively control the spread of Mpox and protect public health.

4.2 Healthcare System Readiness

4.2.1 Healthcare system readiness: A comprehensive overview

A robust healthcare system is essential for effectively responding to public health emergencies. It requires careful planning, adequate resources, and a trained workforce to ensure optimal care delivery during times of crisis. This comprehensive overview will explore key aspects of healthcare system readiness, including hospital capacity, healthcare worker training, triage and treatment guidelines, and infection control measures.

4.2.2 Hospital capacity and surge planning

a) **Bed Capacity:** Ensuring sufficient hospital beds to accommodate a surge in patients during an outbreak.
b) **Staffing:** Adequate staffing levels to provide care for increased patient volumes.
c) **Equipment and Supplies:** Availability of necessary medical equipment, supplies, and medications.
d) **Surge Planning:** Developing contingency plans to expand hospital capacity and allocate resources efficiently.
e) **Alternative Care Sites:** Establishing alternative care sites, such as field hospitals or repurposed facilities, to alleviate pressure on existing hospitals.

4.2.3 Healthcare worker training and protocols

a) **Specialized Training:** Providing healthcare workers with specialized training on disease management, infection control, and emergency response.
b) **Standard Operating Procedures (SOPs):** Developing clear SOPs for various scenarios, including patient triage, isolation, and treatment.
c) **Mental Health Support:** Offering mental health support to healthcare workers to address the psychological toll of working in high-stress environments.
d) **Personal Protective Equipment (PPE):** Ensuring adequate supply and proper use of PPE to protect healthcare workers from exposure.

4.2.4 Triage and treatment guidelines

a) **Prioritization of Care:** Developing triage protocols to prioritize patients based on their medical needs and the severity of their condition.
b) **Treatment Guidelines:** Establishing guidelines for the treatment of patients with specific diseases or conditions.
c) **Evidence-Based Practices:** Ensuring that treatment guidelines are based on the latest scientific evidence.
d) **Continuous Evaluation:** Regularly reviewing and updating treatment guidelines to reflect evolving knowledge and best practices.

4.2.5 Infection control measures

a) **Hand Hygiene:** Implementing strict hand hygiene practices among healthcare workers and patients to prevent the spread of germs.
b) **Isolation:** Isolating patients with infectious diseases to prevent transmission to others.
c) **Environmental Cleaning:** Ensuring regular cleaning and disinfection of healthcare facilities.
d) **Respiratory Hygiene:** Promoting respiratory hygiene practices, such as covering coughs and sneezes.
e) **Waste Management:** Implementing proper waste management procedures to prevent the spread of infectious agents.

4.3 Case Study: COVID-19 Pandemic

The COVID-19 pandemic highlighted the importance of healthcare system readiness. Many countries struggled to cope with the surge in cases due to inadequate hospital capacity, insufficient staffing, and shortages of medical supplies. However, those with well-prepared healthcare systems were better able to manage the crisis and minimize mortality rates.

Table 3. It provides a structured overview of healthcare system readiness regarding monkey pox based on recent research, emphasizing critical factors that influence effective response strategies

Aspect	Details
Definition of Healthcare Readiness	The ability of a healthcare system to prepare for, respond to, and recover from monkey pox outbreaks.
Key Dimensions	- **Surveillance** - **Vaccination Capacity** - **Healthcare Workforce Preparedness** - **Public Health Infrastructure** - **Community Engagement**
Recent Research Findings	- **Surveillance**: Enhanced surveillance systems have been effective in early detection; studies emphasize the need for integrated data systems to monitor outbreaks. - **Vaccination Capacity**: Research indicates that existing vaccine supplies (e.g., JYNNEOS) may not be sufficient during large outbreaks, highlighting the need for stockpiling and rapid distribution plans. - **Workforce Preparedness**: Many healthcare workers reported feeling unprepared for monkey pox; ongoing training and clear protocols are essential for effective response. - **Public Health Infrastructure**: Studies reveal that regions with stronger public health systems (e.g., rapid response teams) are more effective in controlling outbreaks. - **Community Engagement**: Trust-building initiatives with community leaders have shown to improve public compliance with health measures during outbreaks.
Case Studies	- **2022 Monkey pox Outbreak**: Countries with established rapid response mechanisms had better containment strategies. - **Community Health Programs**: Effective outreach in high-risk populations has led to higher vaccination uptake and awareness.
Assessment Tools	- **Readiness Assessment Frameworks**: Tools developed to evaluate specific areas of preparedness for monkey pox outbreaks. - **Surveys and Metrics**: Regular assessments of healthcare workforce readiness and community awareness levels.
Challenges Identified	- Limited vaccine production capacity and distribution logistics. - Stigma and misinformation surrounding monkey pox hinder public health efforts. - Resource allocation disparities between urban and rural healthcare facilities.
Recommendations	- Increase funding for public health initiatives focused on monkey pox preparedness. - Expand training programs for healthcare workers on emerging infectious diseases. - Enhance community outreach to address stigma and improve public understanding of monkey pox.
Future Directions	- Development of targeted vaccination campaigns in at-risk communities. - Strengthening global collaboration for disease surveillance and vaccine sharing. - Ongoing research into treatments and long-term strategies for managing outbreaks.

4.4 Lessons Learned

a) **Early Planning:** The importance of proactive planning and preparedness for potential public health emergencies.

b) **Resource Allocation:** The need for equitable distribution of resources, including healthcare workers, equipment, and supplies.

c) **Intersectoral Collaboration:** The value of collaboration between healthcare providers, public health agencies, and other relevant stakeholders.
d) **Community Engagement:** The importance of involving communities in public health efforts to promote awareness and compliance with prevention measures.

A well-prepared healthcare system is essential for effectively responding to public health emergencies. By investing in hospital capacity, training healthcare workers, developing clear guidelines, and implementing robust infection control measures, countries can improve their resilience and protect the health of their populations.

5. RESEARCH AND DEVELOPMENT

5.1 Research and Development in Monkey pox: A Comprehensive Overview

Research and development (R&D) play a critical role in combating Mpox, a zoonotic viral illness. By understanding the virus, developing effective vaccines and therapeutics, and conducting epidemiological studies, researchers can contribute significantly to the prevention, diagnosis, and treatment of this disease (Carvalho et al., 2024).

5.2 Vaccine Development and Distribution of Monkey Pox Vaccines

The development and distribution of vaccines for monkey pox (now referred to as Mpox) have become an essential part of the global response to this disease, especially after the 2022 outbreak that saw increased cases outside of the traditionally endemic areas in West and Central Africa. Mpox is caused by the Mpox virus, a member of the same family as the smallpox virus, and vaccines that were originally developed for smallpox have shown effectiveness against Mpox as well. This provides an important tool in the fight against the disease, but the distribution of these vaccines presents a range of challenges, particularly in low-income countries and among vulnerable populations.

5.3 Development of Monkey Pox Vaccines

The vaccines used for Monkey Pox are primarily based on the smallpox vaccine, as the two viruses are closely related. There are two main types of vaccines that have been used in response to Mpox outbreaks:

JYNNEOS (also known as Imvamune or Imvanex): This is a live, non-replicating vaccine that was developed specifically for smallpox and later shown to be effective for preventing Mpox. JYNNEOS is a safer alternative to the older smallpox vaccines, especially for individuals with weakened immune systems.

ACAM2000: This is a live, replicating vaccine that is more traditional, based on a modified form of the vaccinia virus, which is closely related to the virus that causes smallpox. However, it can cause more side effects and is generally not recommended for people with compromised immune systems. While these vaccines have been proven effective in preventing Mpox, their production and distribution on a global scale have posed significant challenges.

5.4 Global Distribution of Mpox Vaccines

The global distribution of Mpox vaccines has involved multiple international health organizations, including the World Health Organization (WHO), Gavi, and CEPI (Coalition for Epidemic Preparedness Innovations), which aim to ensure that vaccines reach all parts of the world, particularly in countries at higher risk for outbreaks. However, distributing vaccines globally—especially to low-income countries—faces several challenges:

5.4.1 Limited vaccine supply

The production of vaccines like JYNNEOS and ACAM2000 has not been scaled up sufficiently to meet the global demand, especially during an unexpected outbreak. Although some governments have stockpiled vaccines for use in case of smallpox outbreaks, the sudden resurgence of Mpox has placed strain on available supplies.

- The production of JYNNEOS is limited because it requires specialized facilities for manufacturing, and the vaccines are more expensive to produce compared to older smallpox vaccines.

5.4.2 Cost barriers

The cost of vaccines like JYNNEOS can be prohibitively high for low-income countries, where

public health budgets are often constrained. While organizations like Gavi and CEPI have worked to negotiate lower prices and support procurement, many low-resource countries still face significant barriers in accessing sufficient quantities of vaccine doses. Donor-funded programs have helped subsidize vaccine access for these nations, but there are still concerns about the sustainability of funding in the long term, especially as the global health focus shifts to other emerging diseases.

5.4.3 Supply chain and infrastructure challenges

The cold storage requirements for vaccines like JYNNEOS (which must be kept at very low temperatures) can be challenging to maintain in low-income countries, where cold chain infrastructure may be limited. Even if the vaccines are available, ensuring they remain effective requires robust supply chains for transportation and storage, which are often lacking in remote or underserved areas. Additionally, distributing vaccines to rural and hard-to-reach populations adds another layer of complexity, requiring not only cold storage but also reliable transport systems and local healthcare networks to administer the vaccines.

5.5 Challenges Related to Immunizing Vulnerable Groups

Immunizing vulnerable groups, including those at higher risk of severe disease or exposure to the Mpox virus, presents another significant challenge. Vulnerable populations include:

5.5.1 Healthcare workers

- Healthcare workers are at increased risk due to their direct contact with infected patients. Ensuring that these workers are vaccinated and protected is critical, but logistical barriers, such as limited access to vaccines in healthcare settings, complicate this effort.

5.5.2 People living with HIV/AIDS

Immunocompromised individuals, such as those living with HIV/AIDS, are at greater risk for severe outcomes from Mpox. While JYNNEOS is generally considered safer for immunocompromised individuals compared to ACAM2000, it may still present challenges in terms of access, especially in countries with high rates of HIV. In some cases, these individuals may face additional barriers, such as the need for more specialized healthcare infrastructure and access to antiretroviral therapy (ART), which complicates their ability to receive the Mpox vaccine.

5.5.3 Children and pregnant women

While JYNNEOS is considered safe for use in pregnant women and children over the age of 2, the availability of vaccines in the right formulation for these groups may be limited, and there may be hesitancy regarding their safety, especially in low-income or conservative settings where mistrust of vaccines is more prevalent.

5.5.4 High-risk populations in endemic areas

In areas where Mpox is endemic, such as parts of West and Central Africa, the vaccine is crucial for controlling the spread of the virus. However, low vaccination coverage in these regions, due to logistical and financial constraints, continues to limit the effectiveness of vaccination campaigns.

These regions may also face challenges related to public health awareness and local misinformation, which can contribute to vaccine hesitancy, particularly among communities that may be unfamiliar with the concept of vaccination for a virus like Mpox.

5.5.5 Key populations in the outbreak context

During outbreaks outside of endemic areas, such as in the 2022 global surge, key populations such as men who have sex with men (MSM), who were identified as being at increased risk of transmission, need targeted vaccination campaigns. Reaching these populations often involves addressing both practical barriers (access to clinics or vaccination sites) and sociocultural factors (stigma or discrimination related to sexual orientation).

5.6 Overcoming the Challenges

To address these challenges, several strategies can be employed:

5.6.1 International cooperation and funding

Collaboration between international organizations, governments, and NGOs is essential to ensure that vaccines are provided to low-income countries. Gavi, the Vaccine Alliance, has worked to subsidize vaccine costs and

ensure that vaccines are distributed equitably. Additionally, initiatives like the WHO's Emergency Use Listing (EUL) can facilitate the rapid approval and distribution of vaccines in countries that need them most.

5.6.2 Strengthening health infrastructure

Investments in strengthening health infrastructure, including cold chain systems, healthcare delivery networks, and vaccination programs, are crucial for ensuring that vaccines can be distributed effectively and safely to vulnerable populations.

5.6.3 Vaccine education and public awareness

Vaccine education campaigns that promote awareness of the benefits and safety of vaccines can help address vaccine hesitancy, particularly in communities with limited trust in healthcare systems. Engaging local leaders and healthcare providers in outreach efforts can also build trust and facilitate vaccine uptake.

5.6.4 Targeted vaccination strategies

Focusing on high-risk groups and using targeted vaccination strategies, such as vaccinating healthcare workers, contacts of confirmed cases, and individuals in close contact with high-risk populations, can help to control the spread of the virus more effectively. The global distribution and administration of Mpox vaccines are essential for controlling the spread of the disease, but they face significant barriers, particularly in low-income countries. Limited vaccine supply, logistical challenges, cost issues, and the need for targeted immunization of vulnerable groups all complicate global vaccination efforts. Overcoming these challenges requires coordinated international support, investment in infrastructure, and targeted public health campaigns to ensure that vaccines reach the populations who need them most, both in endemic and non-endemic regions.

5.7 Economic and Social Impacts

5.7.1 Economic and social impacts of monkey pox

Monkey Pox, a zoonotic viral illness, has had significant economic and social implications worldwide. The outbreak has disrupted supply chains, impacted tourism and travel, affected mental health, and necessitated the implementation of economic relief measures and social safety nets.

5.8 Disruption of Supply Chains and Trade

a) **Global Supply Chain Disruptions:** Mpox outbreaks in key manufacturing regions can lead to disruptions in global supply chains, affecting the production and distribution of goods and services.
b) **Trade Restrictions:** Countries may impose trade restrictions on areas with high rates of Mpox transmission, limiting the flow of goods and services.
c) **Economic Losses:** Disruptions in supply chains and trade can result in significant economic
d) losses for businesses, industries, and countries.

5.9 Impact on Tourism and Travel

a) **Travel Restrictions:** Governments may impose travel restrictions on areas with high rates of Mpox transmission, discouraging tourism and travel.
b) **Fear and Uncertainty:** The fear and uncertainty surrounding Mpox can deter tourists from visiting affected regions.
c) **Economic Losses:** The decline in tourism and travel can have a severe impact on the economies of affected regions, particularly those reliant on tourism.

5.10 Mental Health Implications and Social Stigma

a) **Fear and Anxiety:** The fear of contracting Mpox can lead to anxiety, stress, and depression.
b) **Social Isolation:** Individuals with Mpox or those perceived to be at risk may experience social isolation and stigmatization.
c) **Mental Health Impacts:** The mental health implications of Mpox can have a significant impact on individuals, families, and communities.

5.11 Economic Relief Measures and Social Safety Nets

a) **Fiscal Stimulus:** Governments may implement fiscal stimulus measures,

such as tax cuts or increased government spending, to mitigate the economic impact of Mpox (Cao et al., 2024).

b) **Social Safety Nets:** Strengthening social safety nets, such as unemployment benefits and food assistance programs, can help protect vulnerable populations.
c) **Small Business Support:** Providing financial assistance and support to small businesses affected by Mpox.
d) **Job Training and Retraining:** Offering job training and retraining programs to help individuals find new employment opportunities.

5.12 Case Study: Global Impact of COVID-19

The COVID-19 pandemic provides valuable insights into the potential economic and social impacts of Mpox. The pandemic led to widespread disruptions in supply chains, a decline in tourism and travel, increased mental health challenges, and the need for significant economic relief measures.

Lessons Learned:

a) **Proactive Planning:** The importance of proactive planning and preparedness for emerging infectious diseases to mitigate their economic and social impacts.
b) **International Cooperation:** The value of international cooperation in addressing global health crises and minimizing their economic consequences.
c) **Resilience Building:** The need to build resilience in economies and societies to withstand shocks and disruptions.
d) **Social Safety Nets:** The importance of strong social safety nets to protect vulnerable populations during times of crisis.

Mpox has had significant economic and social impacts worldwide. By understanding the potential consequences and implementing appropriate measures, countries can mitigate these impacts and promote recovery (Jandrasits et al.,2024).

6. ETHICAL CONSIDERATIONS

Ethical Considerations in Healthcare: A Comprehensive Overview: Ethical considerations play a crucial role in shaping healthcare systems and ensuring that they operate in a just and equitable manner. This comprehensive overview will explore key ethical principles, including equity and access to healthcare, resource allocation and prioritization, privacy and data protection, and the ethical implications of research and development.

6.1 Equity and Access to Healthcare

a) **Universal Health Coverage (UHC):** Promoting UHC to ensure that everyone has access to quality healthcare services without financial hardship.
b) **Discrimination and Inequality:** Addressing discrimination and inequality in healthcare access based on factors such as race, ethnicity, gender, socioeconomic status, and geographic location.
c) **Cost-Sharing:** Balancing the need for cost-sharing with the importance of ensuring access to essential healthcare services for all.
d) **Health Disparities:** Addressing health disparities and improving health outcomes for marginalized populations.

6.2 Resource Allocation and Prioritization

a) **Scarce Resources:** Allocating scarce healthcare resources in a just and equitable manner.
b) **Prioritization Frameworks:** Developing prioritization frameworks to determine which healthcare services and interventions should receive priority.
c) **Cost-Benefit Analysis:** Using cost-benefit analysis to evaluate the effectiveness and efficiency of different healthcare interventions.
d) **Need-Based Allocation:** Prioritizing healthcare services based on the needs of patients and communities.

6.3 Privacy and Data Protection

a) **Patient Confidentiality:** Protecting patient confidentiality and ensuring that personal health information is handled securely.
b) **Data Privacy Laws:** Complying with data privacy laws and regulations.
c) **Informed Consent:** Obtaining informed consent from patients before collecting and using their personal health information.

d) **Data Sharing:** Balancing the need for data sharing with the importance of protecting patient privacy.

6.4 Ethical Implications of Research and Development

a) **Informed Consent:** Ensuring that research participants provide informed consent and are protected from harm.
b) **Vulnerable Populations:** Protecting vulnerable populations, such as children, the elderly, and those with disabilities, from exploitation in research.
c) **Research Ethics Committees:** Establishing research ethics committees to review and approve research protocols.
d) **Data Integrity:** Maintaining the integrity and accuracy of research data.

6.5 Case Study: COVID-19 Pandemic

The COVID-19 pandemic highlighted the importance of ethical considerations in healthcare. Countries faced difficult decisions regarding resource allocation, vaccine distribution, and the protection of vulnerable populations (Song et al., 2024). Ethical principles guided these decisions and helped ensure that healthcare systems operated in a just and equitable manner.

Lessons Learned:

a) **Transparency and Accountability:** The importance of transparency and accountability in healthcare decision-making.
b) **Community Engagement:** The value of involving communities in decision-making processes to ensure that their needs and concerns are addressed.
c) **Ethical Dilemmas:** The need for careful consideration of ethical dilemmas that arise in healthcare.
d) **Long-Term Impacts:** The importance of considering the long-term impacts of healthcare decisions on individuals, communities, and societies.

Ethical considerations are essential for ensuring that healthcare systems operate in a just and equitable manner. By upholding principles such as equity, access, privacy, and data protection, healthcare providers can promote the well-being of individuals and communities.

7. FUTURE PANDEMICS AND LESSONS LEARNED

7.1 Future Pandemics and Lessons Learned

The COVID-19 pandemic has underscored the urgent need for global preparedness to prevent and mitigate future pandemics. By learning from the lessons of the past, we can strengthen our healthcare systems, improve surveillance and response capabilities, and address the root causes of infectious disease outbreaks.

7.2 Preparedness for Emerging Infectious Diseases

a) **Early Warning Systems:** Investing in early warning systems to detect and monitor emerging infectious diseases.
b) **Surveillance Networks:** Strengthening global surveillance networks to track the spread of diseases and identify potential outbreaks.
c) **Rapid Response Teams:** Establishing rapid response teams to deploy to affected areas and provide on-the-ground support.
d) **Stockpiling of Medical Supplies:** Ensuring adequate stockpiles of essential medical supplies, such as personal protective equipment (PPE), diagnostic tests, and vaccines.
e) **Research and Development:** Investing in research and development to develop new vaccines, therapeutics, and diagnostic tools.

7.3 Strengthening Global Health Security

a) **International Cooperation:** Enhancing international cooperation and coordination to address global health challenges.
b) **WHO Reform:** Strengthening the World Health Organization (WHO) to improve its leadership, governance, and effectiveness.
c) **Financial Commitments:** Increasing financial commitments to global health security to ensure adequate funding for prevention, preparedness, and response efforts.
d) **Equity and Inclusion:** Promoting equity and inclusion in global health initiatives to ensure that all countries and populations have access to essential services.

7.4 Building Resilient Healthcare Systems

a) **Hospital Capacity:** Expanding hospital capacity to accommodate surges in patients during outbreaks.
b) **Healthcare Workforce:** Investing in the training and development of healthcare workers to ensure a skilled and resilient workforce.
c) **Supply Chain Resilience:** Building resilient supply chains to ensure the availability of essential medical supplies and equipment.
d) **Emergency Preparedness:** Developing and implementing emergency preparedness plans to guide responses to public health emergencies.

7.5 Addressing the Root Causes of Pandemics

a) **Zoonotic Disease Prevention:** Implementing measures to prevent the transmission of zoonotic diseases from animals to humans.
b) **Wildlife Trade Regulation:** Regulating the trade in wildlife to reduce the risk of disease transmission.
c) **Habitat Preservation:** Protecting natural habitats to reduce the risk of human-wildlife interactions.
d) **Climate Change Mitigation:** Addressing climate change to reduce the risk of emerging infectious diseases and other health threats.

7.6 Lessons Learned from COVID-19

a) **Early Detection and Response:** The importance of early detection and rapid response to contain outbreaks before they spread.
b) **International Cooperation:** The value of international cooperation in addressing global health crises.
c) **Equity and Inclusion:** The need to ensure equity and inclusion in health interventions to protect vulnerable populations.
d) **Resilience Building:** The importance of building resilient healthcare systems and communities to withstand shocks and disruptions.

Future Outlook: While the threat of future pandemics remains significant, we can take proactive steps to reduce the risk and mitigate their impact. By investing in preparedness, strengthening global health security, building resilient healthcare systems, and addressing the root causes of infectious diseases, we can create a safer and healthier world for generations to come (León-Figueroa et al., 2024).

7.7 Additional Considerations in Mpox: A Comprehensive Overview

7.7.1 Geographic variations in prevalence and impact

The prevalence and impact of Mpox can vary significantly across different geographic regions due to several factors:

a) **Population Density:** Densely populated areas can facilitate the spread of Mpox, while more sparsely populated regions may have lower rates of transmission.
b) **Socioeconomic Factors:** Socioeconomic disparities can influence access to healthcare, vaccination, and prevention measures, leading to variations in Mpox prevalence and impact.
c) **Cultural Practices:** Cultural practices, such as sexual behavior and hygiene practices, can influence the transmission of Mpox.
d) **Environmental Factors:** Geographic location, climate, and environmental conditions can affect the prevalence and distribution of Mpox.

7.7.2 Disparities in access to healthcare and resources

a) **Inequality in Access:** Disparities in access to healthcare and resources can exacerbate the impact of Mpox, particularly in marginalized communities.
b) **Limited Healthcare Infrastructure:** In regions with limited healthcare infrastructure, access to diagnosis, treatment, and prevention services may be constrained.
c) **Financial Barriers:** Financial barriers can prevent individuals from seeking healthcare, leading to delayed diagnosis and treatment.

7.7.3 Role of climate change and environmental factors

a) **Climate Change Impacts:** Climate change can affect the distribution and

prevalence of Mpox by altering the habitats of reservoir hosts and creating favourable conditions for disease transmission.

b) **Environmental Factors:** Environmental factors, such as deforestation and urbanization, can bring humans into closer contact with wildlife that may harbour Mpox.

7.7.4 Long-term consequences of infection and recovery

a) **Post-Mpox Syndrome:** Some individuals may experience long-term health problems, known as post-Mpox syndrome, after recovering from the initial infection.
b) **Mental Health Impacts:** Mpox infection and recovery can have significant mental health consequences, including anxiety, depression, and post-traumatic stress disorder (PTSD).
c) **Stigma and Discrimination:** Individuals who have recovered from Mpox may face stigma and discrimination, affecting their social and economic well-being.

7.7.5 Addressing these considerations

To effectively address these additional considerations, it is essential to:

a) **Strengthen Healthcare Systems:** Invest in strengthening healthcare systems, particularly in marginalized communities, to improve access to diagnosis, treatment, and prevention services.
b) **Promote Equity:** Address disparities in access to healthcare and resources to ensure that everyone has equal opportunities for prevention and treatment.
c) **Implement Climate Change Mitigation Strategies:** Implement climate change mitigation strategies to reduce the risk of emerging infectious diseases.
d) **Promote Environmental Protection:** Protect natural habitats and reduce human-wildlife interactions to prevent the transmission of zoonotic diseases.
e) **Address Mental Health Needs:** Provide mental health support to individuals affected by Mpox and raise awareness about the importance of mental health.
f) **Combat Stigma and Discrimination:** Promote education and awareness to reduce stigma and discrimination associated with Mpox.

8. CONCLUSION

The resurgence of monkey pox, particularly in 2022, has underscored the intricacy of managing infectious diseases in an increasingly interconnected world. Recent developments in research and public health policies have shed light on crucial aspects of the outbreak, highlighting the necessity of taking a diversified strategy to prevent and control it. Recent research has enhanced our understanding of the epidemiology of monkey pox by revealing significant transmission patterns previously overlooked. The virus, which has historically been endemic to particular regions in Central and West Africa, has shown that it is capable of spreading beyond these regions and infecting a wide variety of populations. This transition has led to a re-evaluation of surveillance systems, emphasizing the need for dependable real-time data gathering methods to promptly monitor cases and identify potential outbreaks. The incorporation of cutting-edge genome sequencing technologies has provided researchers with further assistance in tracking transmission channels, which has facilitated the identification of sources of infection and the implementation of effective control measures. Within the realm of monkey pox prevention measures, vaccination has emerged as a fundamental component. The public health response has been largely dependent on the JYNNEOS vaccine, which was specifically developed to protect against orthopox viruses. Studies have shown that immunization not only provides direct protection but also plays a crucial role in reducing transmission rates. There has been a critical need for the creation of vaccination efforts that are strategic and targeted toward high-risk populations. In light of these efforts, it is clear that it is essential to adjust public health campaigns to the particular circumstances and requirements of communities in order to guarantee that everyone has equal access to information and vaccinations. When it comes to preventing the spread of monkey pox, education about public health has proven to be an indispensable component, alongside vaccination. There is a substantial potential for misinformation and stigma associated with the condition to significantly impede preventative efforts. Recent initiatives aimed at enhancing community engagement have proven their ability to foster trust and motivate individuals to pursue immunization and treatment. Communication strategies that are sensitive to different cultures are extremely important since they have the

ability to effectively combat misconceptions and encourage healthy behaviours. Research demonstrates that involving community leaders and healthcare providers in these activities can enhance acceptance and outreach. Discussions have brought the importance of healthcare systems in the fight against monkey pox outbreaks to the forefront. The COVID-19 pandemic has exposed the strengths and limitations of global health systems. When it comes to dealing with future outbreaks, it is absolutely necessary to have preparedness strategies that include lessons learned from COVID-19. For the purpose of ensuring that healthcare systems are able to efficiently deal with newly developing infectious diseases, it is vital to make investments in healthcare infrastructure, staff training, and quick response capabilities. Because early detection and response are essential to the prevention of outbreaks, it is essential that healthcare workers receive ongoing training on how to identify and manage cases of monkey pox. Furthermore, we cannot overstate the importance of effective global collaboration. Infectious diseases do not respect borders, and the recent outbreaks of monkey pox have proven the necessity of coordinated responses on a global scale with the worldwide community. It is possible to improve the global ability to respond to health emergencies by encouraging governments to share resources, data, and best practices with one another. Initiatives that promote equal access to vaccines and treatments in low- and intermediate-income countries are crucial for ensuring universal protection against monkey pox. Researchers are currently testing a number of antiviral therapies to determine their effectiveness against monkey pox, as the study of medicines has advanced. Promising results from research on currently available antivirals, such as tecovirimat, have paved the way for the development of potential treatments that can lessen the severity of the condition. It is crucial to continue research in order to design treatment regimens and investigate the efficacy of new therapeutic drugs, which could significantly reduce the morbidity and mortality associated with monkey pox. In order to effectively combat the spread of monkey pox and prevent its occurrence, a complete approach is required, one that incorporates the latest research findings, public health strategies, and community involvement. Lessons learned from this and other infectious disease outbreaks underscore the importance of taking a proactive approach to addressing global health concerns. Through the prioritization of vaccination, the enhancement of healthcare system preparation, the cultivation of community trust, and the promotion of international collaboration, we may better equip ourselves to prevent and respond to monkey pox and other new infectious diseases in the future. As we navigate the complexities of public health in an increasingly globalized world, we must make a concerted effort to safeguard everyone's health and well-being. The outbreak of monkey pox that occurred in 2022-2023 was a significant public health incident that highlighted the interconnection of infectious illnesses all over the world as well as the significance of having efficient surveillance and response procedures. However, despite the fact that the initial surge of cases has subsided, the virus continues to be a potential threat. For the purpose of limiting future outbreaks, it is essential to have a solid understanding of the factors that contributed to the spread of the outbreak, the effectiveness of preventative measures, and the challenges that healthcare systems face. During the outbreak, it became clear that there is a pressing need for enhanced surveillance and early detection systems in order to identify and manage newly emerging infectious diseases. For the purpose of monitoring the global spread of diseases and enabling prompt responses, it is essential for international health institutions to improve their data exchange and communication with one another. Additionally, investing in research and development is crucial for creating innovative vaccinations, antivirals, and diagnostic tools to tackle future epidemics. Despite the effectiveness of immunization in preventing monkey pox, hurdles in vaccine distribution and accessibility, particularly in countries with low and intermediate incomes, have hampered efforts to manage the outbreak. In order to ensure the safety of health care around the world, it is essential to eliminate these inequities. Additionally, public health campaigns and educational programs are vital for increasing information regarding the transmission of monkey pox, symptoms, and preventative methods. It lets people protect themselves and their communities. In order to improve global health preparedness and response capacity, it is necessary to make use of the lessons learned from the monkey pox epidemic. This is because the challenge of new infectious diseases continues to rise. By investing in surveillance systems, research, and equal access to healthcare, we can mitigate the impact of future outbreaks and protect global public health.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

Adegboye, O., Alele, F., Pak, A., Alakunle, E., Emeto, T., Leggat, P., & Okeke, M. (2024). Monkeypox outbreak 2022, from a rare disease to global health emergence: Implications for travelers. *Poxviruses*, 355-368. https://doi.org/10.1016/B978-0-12-818891-1.00026-0

Akkilic, A. N., Sabir, Z., Bhat, S. A., & Bulut, H. (2024). A radial basis deep neural network process using the Bayesian regularization optimization for the monkeypox transmission model. *Expert Systems with Applications*, *235*, 121257. https://doi.org/10.1016/j.eswa.2023.121257

Araf, Y., Nipa, J. F., Naher, S., Maliha, S. T., Rahman, H., Arafat, K. I., ... & Zheng, C. (2024). Insights into the transmission, host range, genomics, vaccination, and current epidemiology of the monkeypox virus. *Veterinary Medicine International*, 2024(1), 8839830. https://doi.org/10.1155/2024/8839830

Cai, Y., Zhang, X., Zhang, K., Liang, J., Wang, P., Cong, J., ... & Wei, B. (2024). The global patent landscape of emerging infectious disease monkeypox. *BMC Infectious Diseases*, *24*(1), 403. https://doi.org/10.1186/s12879-024-08402-w

Can, G., Perk, B., Çitil, B. E., Büyüksünetçi, Y. T., & Anık, U. (2024). Electrochemical immunoassay platform for human monkeypox virus detection. *Analytical Chemistry*. https://doi.org/10.1021/acscentsci.4b01474

Cao, Y., Fang, W., Chen, Y., Zhang, H., Ni, R., & Pan, G. (2024). Simulating the impact of optimized prevention and control measures on the transmission of monkeypox in the United States: A model-based study. *Journal of Medical Virology*, 96(2), e29419. https://doi.org/10.1002/jmv.29419

Carvalho, E. M., Medeiros, M., Veloso, V. G., Biancardi, A. L., & Curi, A. L. L. (2024). Monkeypox infection causing conjunctival vesicles and anterior uveitis. *Ocular Immunology and Inflammation*, 32(3), 266-267. https://doi.org/10.1080/09273948.2023.2245681

Cevik, M., Tomori, O., Mbala, P., Scagliarini, A., Petersen, E., Low, N., ... & Blumberg, L. (2024). The 2023–2024 multi-source mpox outbreaks of *Clade I MPXV* in sub-Saharan Africa: Alarm bell for Africa and the world. *International Journal of Infectious Diseases, 146*.

de Araújo, L. P., Silva, E. N., Corsetti, P. P., & de Almeida, L. A. (2024). Shared immunogenic epitopes between host entry and exit proteins from monkeypox and *Alaskapox* viruses. *The Lancet Microbe*.

de Oliveira Maldonado, J. V., Oliveira, M. Y. S. T., Stocki, J. F., Pessoa, F. S., de Sá, J. B., de Albuquerque, D. M. L., ... & Malta, A. L. S. (2024). Vacinas contra *Monkeypox*: Uma revisão sistemática da eficácia global e desafios em saúde pública. *Caderno Pedagógico*, *21*(8), e7165-e7165.

Fakhri-Demeshghieh, A., Akbarein, H., & Almasi, P. (2024). Epidemiology of human monkeypox about the 2022 outbreak: A narrative review. *Journal of Community Health Research*. https://doi.org/10.30476/jchr.2024.967535

Fantin, R. F., & Coelho, C. H. (2024). Human antibody responses to circulating monkeypox virus emphasise the need for the first *mpox*-specific vaccine. *The Lancet Microbe, 5*(3), e204-e205.

Gehre, F., Nzeyimana, E., Lagu, H. I., Achol, E., Nguinkal, J. A., Kezakarayagwa, E., ... & Affara, M. (2024). Rapid regional mobile laboratory response and genomic monkeypox virus (*MPXV*) surveillance in seven East African Community partner states, August 2024: Preparedness activities for the ongoing outbreak. *Eurosurveillance, 29*(35), 2400541.

Ghana, L. (2024). Mpox strikes once more in 2024: Declared again as a public health emergency of international concern. *Travel Medicine and Infectious Disease, 61*, 102753.

Godinho, F. M., Bermann, T. D. L., de Oliveira, M. M., Barcellos, R. B., Ruivo, A. P., de Melo, V. H., ... & Salvato, R. S. (2024). Endemic transmission and international introduction of monkeypox virus in Southern Brazil between 2022-2023. *medRxiv*. https://doi.org/10.1101/2024-06

Guagliardo, S. A. J. (2024). Monkeypox virus infections after 2 preexposure doses of JYNNEOS vaccine—United States, May 2022–May 2024. *MMWR. Morbidity and Mortality Weekly Report , 73*.

Guo, L., Song, R., Zhang, Q., Li, D., Chen, L., Fang, M., ... & Wang, J. (2024). Profiling of viral load, antibody, and inflammatory response of people with monkeypox during hospitalization: A prospective longitudinal cohort study in China. *Ebiomedicine*, 106. https://doi.org/10.1016/j.ebiom.2024.103568

Haque, M. A., Halder, A. S., Hossain, M. J., & Islam, M. R. (2024). Prediction of potential public health risk of the recent multicountry monkeypox outbreak: An update after the end declaration of global public health emergency. *Health Science Reports, 7*(6), e2136.

Hemati, S., & Mohammadi-Moghadam, F. (2024). A systematic review on environmental perspectives of monkeypox virus. *Reviews on Environmental Health, 39*(2), 363-370.

Indiastari, D., Fajar, J. K., Tamara, F., Runesi, O., Hakim, L. N., Chotimah, K., ... & Dzhyvak, V. (2024). Global prevalence and determinants associated with the acceptance of monkeypox vaccination. *Narra J, 4*(2), e866-e866.

Ismael, S. S., Sadiq, A. J., & Barwary, N. J. S. (2024). Why did the monkeypox virus raise its head again in 2024?

Jandrasits, D., Züst, R., Siegrist, D., Engler, O. B., Weber, B., Schmidt, K. M., & Jonsdottir, H. R. (2024). Third-generation smallpox vaccines induce low-level cross-protecting neutralizing antibodies against monkeypox virus in laboratory workers. *Heliyon*, 10(10). https://doi.org/10.1016/j.heliyon.2024.e11192

Khan, G., & Perveen, N. (2024). The 2022 monkeypox outbreak 1 year on: The 5 Ws. *Reviews in Medical Virology, 34*(1), e2489.

Lamas-Francis, D., Treviño, M., Pérez-Freixo, H., Martínez-Perez, L., Touriño, R., & Rodríguez-Ares, T. (2024). Corneal ulcer due to monkeypox infection. *Ocular Immunology and Inflammation*, 32(3), 259-261. https://doi.org/10.1080/09273948.2023.2245680

León-Figueroa, D. A., Barboza, J. J., & Valladares-Garrido, M. J. (2024). Sources of information on monkeypox virus infection: A systematic review with meta-analysis. *BMC Public Health*, *24*(1), 276. https://doi.org/10.1186/s12889-024-15817-2

LHAMO, C., SELDOM, D., & SINGH, A. P. (2022). Monkeypox: A detailed study. *Journal of Disease and Global Health*, 15(2), 1-5.

Li, B., Wang, W., Zhao, L., Li, M., Yan, D., Li, X., ... & Liao, Y. (2024). Aggregation-induced emission-based macrophage-like nanoparticles for targeted photothermal therapy and virus transmission blockage in monkeypox. *Advanced Materials*, *36*(9), 2305378. https://doi.org/10.1002/adma.202305378

Liu, W., Zhang, E., Li, W., Lv, R., Lin, Y., Xu, Y., ... & Li, Y. (2024). Advances and challenges of monkeypox detection technology. *Biosafety and Health*. https://doi.org/10.1016/j.bsheal.2024.04.005

Mattiuzzi, C., Henry, B. M., Rizk, J. G., & Lippi, G. (2024). Mpox (monkeypox) diagnostic kits–September 2024. *Diagnosis*. https://doi.org/10.1515/dx-2024-0281

McCollum, A. M., & Damon, I. K. (2014). Human monkeypox. *Clinical Infectious Diseases, 58*(2), 260-267.

Mitjà, O., Ogoina, D., Titanji, B. K., Galvan, C., Muyembe, J. J., Marks, M., & Orkin, C. M. (2023). Monkeypox. *The Lancet*, *401*(10370), 60-74. https://doi.org/10.1016/S0140-6736(22)02128-X

Monzón, S., Varona, S., Negredo, A., Vidal-Freire, S., Patiño-Galindo, J. A., Ferressini-Gerpe, N., ... & Palacios, G. (2024). Monkeypox virus genomic accordion strategies. *Nature Communications, 15*(1), 3059.

Murhula Sr, L., Udahemuka, J. C., Schuele, L., Nieuwenhuijse, D. F., Ndishimye, P., Boter, M., ... & Koopmans, M. (2024). Mapping and sequencing of cases from an

ongoing outbreak of *Clade Ib* monkeypox virus in South Kivu, Eastern Democratic Republic of the Congo between September 2023 to June 2024. *medRxiv*. https://doi.org/10.1101/2024-09

Natami, M., Gorgzadeh, A., Gholipour, A., Fatemi, S. N., Firouzeh, N., Zokaei, M., ... & Kalavi, S. (2024). An overview on mRNA-based vaccines to prevent monkeypox infection. *Journal of Nanobiotechnology*, 22. https://doi.org/10.1186/s12951-024-02254-9

Oladimeji, A. M., Afe, A. J., Carillo, L., Hundley, C., Zhang, Y., Long, S., ... & Persse, D. (2024). Epidemiology and control of monkeypox outbreak in Houston, Texas. *Global Health Journal*, 8(3), 133-139. https://doi.org/10.1016/j.glohj.2024.02.001

Pal, M., Rebuma, T., Berhanu, W., Endale, B., & Zende, R. (2024). Monkeypox: A new challenge in global health security. *American Journal of Epidemiology, 12*(3), 37-43.

Patauner, F., Gallo, R., Durante-Mangoni, E., & Bertolino, L. (2024). Monkeypox infection, 18 months later: A vanishing epidemic? *European Journal of Internal Medicine, 122*, 35-37.

Rahmani, E., Bayat, Z., Farrokhi, M., Karimian, S., Zahedpasha, R., Sabzehie, H., ... & Farrokhi, M. (2024). Monkeypox: A comprehensive review of virology, epidemiology, transmission, diagnosis, prevention, treatment, and artificial intelligence applications. *Archives of Academic Emergency Medicine*, *12*(1), e70. https://doi.org/10.22037/aaem.v12i1.162

Ravichandran, N. (2024). Monkeypox in Europe: Epidemiology, risk factors and implications for public health actions—a scoping review study. *medRxiv*. https://doi.org/10.1101/2024-08

Saladrigas, A., Sabater-Cruz, N., Gil, M. A., Lázaro-Rodríguez, V., Caminal-Caramés, M., Conversa, S., & Del Campo, Z. (2024). Acute unilateral conjunctivitis as first manifestation of monkeypox viral infection after the 2023 vaccination campaign. *Journal Français d'Ophtalmologie*, 104318. https://doi.org/10.1016/j.jfo.2024.04.029

Saloni, S., Soman, B., Tanti, A., Goyal, A. K., & Kumar, P. (2024). Global resurgence of monkeypox (*mpox*) virus: A review of current outbreaks and public health strategies. *The Evidence*, *2*(3).

Scarpa, F., Azzena, I., Ciccozzi, A., Branda, F., Locci, C., Perra, M., ... & Sanna, D. (2024). Update of the genetic variability of monkeypox virus *Clade IIb* Lineage B.1. *Microorganisms, 12*(9), 1874.

Schuele, L., Masirika, L. M., Udahemuka, J. C., Siangoli, F. B., Mbiribindi, J. B., Ndishimye, P., ... & Molenkamp, R. (2024). Real-time PCR assay to detect the novel *Clade Ib* monkeypox virus, September 2023 to May 2024. *Eurosurveillance, 29*(32), 2400486.

Song, S., Ren, Z., Chen, J., Li, M., Jiang, Y., Liu, Y., ... & Yang, Y. (2024). Analysis of binding and authentic virus-neutralizing activities of immune sera induced by various monkeypox virus antigens. *Immunologic Research*, 1-6. https://doi.org/10.1007/s12026-024-10072-y

Svecova, D. (2024). Update on monkeypox virus infection. *Journal of Medicine and Healthcare, SRC/JMHC-344*. https://doi.org/10.47363/JMHC/2024 (6), 274, 2-3.

Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., ... & Orkin, C. M. (2022). Monkeypox virus infection in humans across 16 countries—April–June 2022. *New England Journal of Medicine, 387*(8), 679-691.

Ulaeto, D., Agafonov, A., Burchfield, J., Carter, L., Happi, C., Jakob, R., ... & Lewis, R. F. (2023). New nomenclature for *mpox* (monkeypox) and monkeypox virus clades. *The Lancet Infectious Diseases, 23*(3), 273-275.

Venkateswaran, N., Krishnan, V., Sarwar, J., Nelson, W. M., & Venkateswaran, K. S. (2024). A-270 Evaluation of a multiplex panel to determine antibody profile to monkeypox virus in vaccinated, exposed, and naïve individuals. *Clinical Chemistry, 70*(Supplement_1), hvae106-267.

Wawina-Bokalanga, T., Akil-Bandali Sr, P., Kinganda Lusamaki, E., Lokilo, E., Jansen, D., Amuri-Aziza, A., ... & Placide, M. (2024). Co-circulation of clade Ia and Ib monkeypox virus in Kinshasa Province, Democratic Republic of the Congo, July-

August 2024. *medRxiv*. https://doi.org/10.1101/2024.09.11.23216779

Zheng, Q., Bao, C., Li, P., De Vries, A. C., Giordano, G., & Pan, Q. (2022). Projecting the impact of testing and vaccination on the transmission dynamics of the 2022 monkeypox outbreak in the USA. *Journal of Travel Medicine, 29*(8), taac101.

Peer-review history:
The peer review history for this paper can be accessed here:
https://prh.mbimph.com/review-history/4315